Literature DB >> 28098533

Azithromycin-Nonsusceptible Shigella flexneri 3a in Men Who Have Sex with Men, Taiwan, 2015-2016.

Ying-Shu Liao, Yen-Yi Liu, Yi-Chun Lo, Chien-Shun Chiou.   

Abstract

We report an outbreak of azithromycin-nonsusceptible Shigella flexneri 3a infection in Taiwan associated with men who have sex with men. The bacterial strains belonged to the sublineage A of a recently reported outbreak lineage associated with men who have sex with men, characterized by reduced azithromycin susceptibility and circulation in shigellosis low-risk regions.

Entities:  

Keywords:  Shigella flexneri; Taiwan; antimicrobial resistance; azithromycin; bacteria; dysentery; enteric infections; men who have sex with men; sexually transmitted infections; shigella

Mesh:

Substances:

Year:  2016        PMID: 28098533      PMCID: PMC5324798          DOI: 10.3201/eid2302.161260

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Shigellosis among men who have sex with men (MSM) is a major public health concern worldwide (,). Shigella flexneri serotype 3a was responsible for a prolonged MSM-associated outbreak in England and Wales initially detected in 2009 and ongoing at the time of study publication (). More recently, S. flexneri 3a strains with a genetic lineage distinct from Africa- and Asia-associated lineages were identified among MSM in Europe, Australia, and North America (). All strains in this lineage carried a mobile element with 4 antimicrobial resistance genes (blaOXA-1, catA1, aadA1, and tetB), and most recently emerging strains harbored a conjugative IncFII plasmid pKSR100, which conferred high-level resistance to azithromycin (). During 2005–2014, the incidence of domestically acquired shigellosis in Taiwan was low (0.7/100,000 persons) (). Shigellosis is reported through the Web-based National Notifiable Disease Surveillance System (NDSS), which has been in operation since 1997 to monitor all notifiable diseases in Taiwan (,). The NDSS detected the first shigellosis outbreak in MSM during March–May 2015; the outbreak was determined to be caused by the global spread of a ciprofloxacin-resistant S. sonnei clone (). During June 2015–May 2016, a total of 200 shigellosis cases were reported to the NDSS, of which 21 were domestically acquired S. flexneri 3a infections in northern and central Taiwan. All 21 of the S. flexneri 3a infections were in men 22–44 years of age, including 17 self-reported MSM. Of the 21 case-patients, most had reported other infections before S. flexneri 3a diagnosis: HIV (n = 16), 0–162 (median 49) months earlier; syphilis (n = 17), 0–85 (median 9.5) months earlier; gonorrhea (n = 6), 14–130 (median 26) months earlier; amebiasis (n = 2), 0–112 (median 56) months earlier; acute hepatitis A (n = 1), 0 months earlier; and S. sonnei infection (n = 1), 3 months earlier. We tested the 21 S. flexneri 3a isolates for antimicrobial resistance by using a custom-made 96-well Sensititer MIC panel (Trek Diagnostic Systems Ltd., West Grinstead, UK) and the Etest kit (bioMérieux, Marcy l’Etoile, France). All 21 were resistant to ampicillin, chloramphenicol, streptomycin, and tetracycline, and 19 were nonsusceptible to azithromycin (MIC 64–96 μg/mL). We also used the PulseNet pulsed-field gel electrophoresis (PFGE) protocol to analyze the isolates () and compared the PFGE patterns with those of 30 S. flexneri 3a isolates isolated in Taiwan during 2000–2011. The NotI digested PFGE patterns of 20/21 of the isolates were identical to the earlier isolates, and the remaining isolate showed a highly similar pattern. Clustering analysis of the PFGE patterns by using BioNumerics version 6.6 software (Applied Maths, Sint-Martens-Latem, Belgium) revealed that the 21 isolates were genetically distant from the 2000–2011 S. flexneri 3a isolates. We used the Illumina MiSeq platform (Illumina, San Diego, CA, USA) for whole-genome sequencing of 4 isolates, of which 3 were azithromycin-nonsusceptible (codes R15.1162, R16.001, and R16.0013) and 1 was azithromycin-susceptible (R15.3406). We deposited the raw sequence reads in the National Center for Biotechnology Information Short Read Archive database (accession no. SRP080176; BioProject PRJNA335684). We used CLC Genomics Workbench version 9.0.1 (CLC bio, Aarhus, Denmark) for de novo assembly of the reads. We uploaded contigs for each isolate to the website of Center for Genome Epidemiology (http://www.genomicepidemiology.org/) and used its tools to identify sequence type (Multi Locus Sequnce Typing toolkit), plasmid type (PlasmidFinder), and antimicrobial resistance genes (ResFinder 2.1). The 4 isolates were sequence type 245 (ST245), harbored plasmids belonging to incompatibility groups IncFII and Col, and had resistance genes blaOXA-1, catA1, aadA1, tetB, ermB, mphA, and blaTEM. Although isolate R15.3406 carried an intact mphA gene, it was phenotypically azithromycin susceptible. We compared genome single-nucleotide polymorphisms and constructed trees by using the CSI Phylogeny pipeline (https://cge.cbs.dtu.dk/services/CSIPhylogeny/) () to infer phylogenetic relationships between the 4 isolates and the 331 strains used in the study by Baker et al. (). These analyses showed that the 4 isolates recovered in Taiwan belonged to the sublineage A of the MSM-associated outbreak lineage reported by Baker et al. (). In conclusion, we report an azithromycin-nonsusceptible S. flexneri 3a outbreak associated with MSM in Taiwan. The 21 isolates were genetically distant from the S. flexneri 3a isolates recovered in Taiwan from 2000–2011 and belonged to the sublineage A of the recently reported MSM-associated outbreak lineage characterized by reduced azithromycin susceptibility and circulation in shigellosis low-risk regions (). The introduction of this MSM-associated S. flexneri 3a lineage into Taiwan in 2015 illustrates that the pathogen can spread rapidly across continents, possibly through intensified sexual networks among MSM (,). We recommend continued surveillance for antimicrobial resistance genes in S. flexneri to inform clinical management of shigellosis among MSM and public health interventions where needed, including appropriate antimicrobial drug stewardship.
  9 in total

1.  Intensified shigellosis epidemic associated with sexual transmission in men who have sex with men--Shigella flexneri and S. sonnei in England, 2004 to end of February 2015.

Authors:  I Simms; N Field; C Jenkins; T Childs; V L Gilbart; T J Dallman; P Mook; P D Crook; G Hughes
Journal:  Euro Surveill       Date:  2015-04-16

2.  Another perfect storm: Shigella, men who have sex with men, and HIV.

Authors:  Demetre C Daskalakis; Martin J Blaser
Journal:  Clin Infect Dis       Date:  2006-12-29       Impact factor: 9.079

3.  Intercontinental dissemination of azithromycin-resistant shigellosis through sexual transmission: a cross-sectional study.

Authors:  Kate S Baker; Timothy J Dallman; Philip M Ashton; Martin Day; Gwenda Hughes; Paul D Crook; Victoria L Gilbart; Sandra Zittermann; Vanessa G Allen; Benjamin P Howden; Takehiro Tomita; Mary Valcanis; Simon R Harris; Thomas R Connor; Vitali Sintchenko; Peter Howard; Jeremy D Brown; Nicola K Petty; Malika Gouali; Duy Pham Thanh; Karen H Keddy; Anthony M Smith; Kaisar A Talukder; Shah M Faruque; Julian Parkhill; Stephen Baker; François-Xavier Weill; Claire Jenkins; Nicholas R Thomson
Journal:  Lancet Infect Dis       Date:  2015-04-27       Impact factor: 25.071

4.  Standardization of pulsed-field gel electrophoresis protocols for the subtyping of Escherichia coli O157:H7, Salmonella, and Shigella for PulseNet.

Authors:  Efrain M Ribot; M A Fair; R Gautom; D N Cameron; S B Hunter; B Swaminathan; Timothy J Barrett
Journal:  Foodborne Pathog Dis       Date:  2006       Impact factor: 3.171

5.  Ongoing outbreak of Shigella flexneri serotype 3a in men who have sex with men in England and Wales, data from 2009-2011.

Authors:  M L Borg; A Modi; A Tostmann; M Gobin; J Cartwright; C Quigley; P Crook; N Boxall; J Paul; T Cheasty; N Gill; G Hughes; I Simms; I Oliver
Journal:  Euro Surveill       Date:  2012-03-29

6.  The worldwide spread of ciprofloxacin-resistant Shigella sonnei among HIV-infected men who have sex with men, Taiwan.

Authors:  C-S Chiou; H Izumiya; M Kawamura; Y-S Liao; Y-S Su; H-H Wu; W-C Chen; Y-C Lo
Journal:  Clin Microbiol Infect       Date:  2016-01-20       Impact factor: 8.067

7.  National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.

Authors:  Yi-Chun Lo; Mao-Song Tsai; Hsin-Yun Sun; Chien-Ching Hung; Jen-Hsiang Chuang
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

8.  Solving the problem of comparing whole bacterial genomes across different sequencing platforms.

Authors:  Rolf S Kaas; Pimlapas Leekitcharoenphon; Frank M Aarestrup; Ole Lund
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

9.  Prevalent and incident HIV diagnoses among Entamoeba histolytica-infected adult males: a changing epidemiology associated with sexual transmission--Taiwan, 2006-2013.

Authors:  Yi-Chun Lo; Dar-Der Ji; Chien-Ching Hung
Journal:  PLoS Negl Trop Dis       Date:  2014-10-09
  9 in total
  13 in total

1.  A tale of two plasmids: contributions of plasmid associated phenotypes to epidemiological success among Shigella.

Authors:  P Malaka De Silva; George E Stenhouse; Grace A Blackwell; Rebecca J Bengtsson; Claire Jenkins; James P J Hall; Kate S Baker
Journal:  Proc Biol Sci       Date:  2022-08-03       Impact factor: 5.530

2.  Prevalence of Plasmid-Mediated Determinants With Decreased Susceptibility to Azithromycin Among Shigella Isolates in Anhui, China.

Authors:  Yanyan Liu; Hongru Li; Na Lv; Yalong Zhang; Xihai Xu; Ying Ye; Yufeng Gao; Jiabin Li
Journal:  Front Microbiol       Date:  2020-06-30       Impact factor: 5.640

3.  Genetic Mechanisms behind the Spread of Reduced Susceptibility to Azithromycin in Shigella Strains Isolated from Men Who Have Sex with Men in Québec, Canada.

Authors:  Khadidja Yousfi; Christiane Gaudreau; Pierre A Pilon; Brigitte Lefebvre; Matthew Walker; Éric Fournier; Florence Doualla Bell; Christine Martineau; Jean Longtin; Sadjia Bekal
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  Acute Bacterial Gastroenteritis.

Authors:  James M Fleckenstein; F Matthew Kuhlmann; Alaullah Sheikh
Journal:  Gastroenterol Clin North Am       Date:  2021-04-23       Impact factor: 3.806

5.  An adult case with shigellosis-associated encephalopathy.

Authors:  Heleen Joséphine Schuster; Michelle Gompelman; Wim Ang; Albertus Jozef Kooter
Journal:  BMJ Case Rep       Date:  2018-01-18

6.  Horizontal antimicrobial resistance transfer drives epidemics of multiple Shigella species.

Authors:  Kate S Baker; Timothy J Dallman; Nigel Field; Tristan Childs; Holly Mitchell; Martin Day; François-Xavier Weill; Sophie Lefèvre; Mathieu Tourdjman; Gwenda Hughes; Claire Jenkins; Nicholas Thomson
Journal:  Nat Commun       Date:  2018-04-13       Impact factor: 14.919

7.  Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent Shigella flexneri.

Authors:  Molly C McCloskey; Shareef Shaheen; Lesley Rabago; Matthew A Hulverson; Ryan Choi; Lynn K Barrett; Samuel L M Arnold
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

8.  Shigella: Antibiotic-Resistance Mechanisms And New Horizons For Treatment.

Authors:  Reza Ranjbar; Abbas Farahani
Journal:  Infect Drug Resist       Date:  2019-10-07       Impact factor: 4.003

9.  Persistent Transmission of Shigellosis in England Is Associated with a Recently Emerged Multidrug-Resistant Strain of Shigella sonnei.

Authors:  Megan Bardsley; Claire Jenkins; Holly D Mitchell; Amy F W Mikhail; Kate S Baker; Kirsty Foster; Gwenda Hughes; Timothy J Dallman
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

10.  Azithromycin non-susceptible Shigella circulating in Israel, 2014-2016.

Authors:  Analía V Ezernitchi; Elizabeta Sirotkin; Dana Danino; Vered Agmon; Lea Valinsky; Assaf Rokney
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.